Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Epilepsy × Sulfasalazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 2 Signs and Symptoms 1 Psoriasis 1 Nutrition Disorders 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Insulin Resistance 1 Inflammatory Bowel Diseases 1 Glioma 1 Gastroparesis 1 Feeding and Eating Disorders 1 Esophageal Neoplasms 1 Epilepsy 1 Dumping Syndrome 1 Diarrhea 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1 Arthritis, Rheumatoid 1

Interventions

Sirolimus 4 LY3295668 erbumine 3 Everolimus 3 Medical Marijuana 2 Anticonvulsants 2 ziprasidone 1 perampanel 1 enzalutamide 1 clevidipine 1 brivaracetam 1 Zolpidem 1 Warfarin 1 Vigabatrin 1 Vecuronium Bromide 1 Vancomycin 1 Tranexamic Acid 1 Topotecan 1 Tobramycin 1 Therapeutic Touch 1 Temozolomide 1 TAS-119 1 Surgical Procedures, Operative 1 Sulfasalazine 1 Spironolactone 1 Sevoflurane 1 Sevelamer 1 Saline Solution 1 Rocuronium 1 Registries 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05664464 2024-05-10

GLUGLIO

University of Zurich

Phase 1/2 Recruiting

Epilepsy, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡